Jeremy Bender Sells 12,500 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock
Jeremy Bender Sells 12,500 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) CEO Jeremy Bender sold 12,500 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, March 7th. The stock was sold at an average price of $20.01, for a total value of $250,125.00. Following the completion of the sale, the chief executive officer now directly owns 1,174,276 shares of the company's stock, valued at approximately $23,497,262.76. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Day One Biopharmaceuticals, Inc.（納斯達克股票代碼：DAWN — 獲取評級）首席執行官傑里米·本德爾在3月7日星期二的交易中出售了Day One Biopharmaceuticals的12,500股股票。該股票的平均售價爲20.01美元，總價值爲250,125.00美元。出售完成後，首席執行官現在直接擁有該公司1,174,276股股票，價值約23,497,262.76美元。此次出售是在向美國證券交易委員會提交的一份文件中披露的，該文件可通過以下方式獲取 這個超鏈接。
Jeremy Bender also recently made the following trade(s):
傑里米·本德爾最近還進行了以下交易：
- On Thursday, February 16th, Jeremy Bender sold 3,022 shares of Day One Biopharmaceuticals stock. The stock was sold at an average price of $19.57, for a total value of $59,140.54.
- On Monday, January 23rd, Jeremy Bender sold 12,500 shares of Day One Biopharmaceuticals stock. The stock was sold at an average price of $22.00, for a total value of $275,000.00.
- On Wednesday, December 21st, Jeremy Bender sold 12,500 shares of Day One Biopharmaceuticals stock. The shares were sold at an average price of $20.32, for a total value of $254,000.00.
- 2月16日星期四，傑里米·本德爾出售了Day One Biopharmaceuticals的3,022股股票。該股票的平均售價爲19.57美元，總價值爲59,140.54美元。
- 1月23日星期一，傑里米·本德爾出售了Day One Biopharmaceuticals的12,500股股票。該股票的平均售價爲22.00美元，總價值爲27.5萬美元。
- 12月21日星期三，傑里米·本德爾出售了Day One Biopharmaceuticals的12,500股股票。這些股票的平均售價爲20.32美元，總價值爲25.4,000.00美元。
Day One Biopharmaceuticals Stock Performance
第一天生物製藥股票表現
Shares of DAWN stock opened at $18.58 on Friday. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $5.44 and a fifty-two week high of $28.35. The stock has a 50 day moving average price of $20.73 and a two-hundred day moving average price of $20.96. The company has a market capitalization of $1.37 billion, a P/E ratio of -8.56 and a beta of -1.94.
週五，DAWN股票開盤價爲18.58美元。Day One Biopharmaceuticals, Inc.創下五十二週低點5.44美元，創下五十二週高點28.35美元。該股的50天移動平均價格爲20.73美元，兩百天移動平均價格爲20.96美元。該公司的市值爲13.7億美元，市盈率爲-8.56，beta值爲-1.94。
Institutional Trading of Day One Biopharmaceuticals
第一天生物製藥的機構交易
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Quantbot Technologies LP bought a new stake in Day One Biopharmaceuticals in the second quarter valued at approximately $51,000. UBS Group AG bought a new stake in Day One Biopharmaceuticals in the second quarter valued at approximately $69,000. Amalgamated Bank lifted its position in Day One Biopharmaceuticals by 21.0% in the third quarter. Amalgamated Bank now owns 3,577 shares of the company's stock valued at $72,000 after purchasing an additional 620 shares during the last quarter. California State Teachers Retirement System increased its stake in shares of Day One Biopharmaceuticals by 58.6% during the first quarter. California State Teachers Retirement System now owns 9,687 shares of the company's stock valued at $96,000 after buying an additional 3,581 shares during the period. Finally, American International Group Inc. increased its stake in shares of Day One Biopharmaceuticals by 92.7% during the first quarter. American International Group Inc. now owns 11,294 shares of the company's stock valued at $112,000 after buying an additional 5,434 shares during the period. Institutional investors own 86.08% of the company's stock.
對沖基金和其他機構投資者最近買入和賣出了該股的股票。Quantbot Technologies LP在第二季度收購了Day One Biopharmaceuticals的新股份，價值約51,000美元。瑞銀集團股份公司在第二季度收購了Day One Biopharmaceuticals的新股份，價值約爲69,000美元。合併銀行在第三季度將其在第一天生物製藥的頭寸提高了21.0％。合併銀行在上個季度又購買了620股股票後，現在擁有該公司3577股股票，價值72,000美元。加利福尼亞州教師退休系統在第一季度將其在Day One Biopharmaceuticals的股份增加了58.6％。加州州立教師退休系統在此期間又購買了3581股股票後，現在擁有該公司9,687股股票，價值96,000美元。最後，美國國際集團公司在第一季度將其在Day One Biopharmaceuticals的股份增加了92.7％。美國國際集團公司在此期間又購買了5,434股股票後，現在擁有該公司11,294股股票，價值11.2萬美元。機構投資者擁有該公司86.08％的股票。
Wall Street Analysts Forecast Growth
華爾街分析師預測增長
A number of research analysts have weighed in on the company. Capital One Financial assumed coverage on Day One Biopharmaceuticals in a report on Wednesday, February 8th. They set an "overweight" rating and a $40.00 target price for the company. Oppenheimer began coverage on Day One Biopharmaceuticals in a report on Thursday, February 2nd. They set a "market perform" rating for the company. Piper Sandler boosted their price objective on Day One Biopharmaceuticals from $40.00 to $45.00 and gave the stock an "overweight" rating in a report on Sunday, January 8th. HC Wainwright reissued a "buy" rating and set a $45.00 price objective on shares of Day One Biopharmaceuticals in a report on Tuesday. Finally, Needham & Company LLC reissued a "buy" rating and set a $48.00 price objective on shares of Day One Biopharmaceuticals in a report on Tuesday. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $44.14.
許多研究分析師對該公司進行了權衡。Capital One Financial在2月8日星期三的一份報告中假設對第一天生物製藥進行了報道。他們爲公司設定了 “增持” 評級和40.00美元的目標價格。奧本海默在2月2日星期四的一份報告中開始報道第一天生物製藥。他們爲公司設定了 “市場表現” 評級。派珀·桑德勒將第一天生物製藥公司的目標股價從40.00美元上調至45.00美元，並在1月8日星期日的一份報告中將該股評爲 “增持”。HC Wainwright在週二的一份報告中重新發布了 “買入” 評級，並對Day One Biopharmaceuticals的股票設定了45.00美元的目標股價。最後，Needham & Company LLC在週二的一份報告中重新發布了 “買入” 評級，並將Day One Biopharmaceuticals股票的目標股價設定爲48.00美元。一位分析師對該股進行了持有評級，七位分析師對該股發佈了買入評級。根據Marketbeat.com的數據，Day One Biopharmaceuticals目前的共識評級爲 “適度買入”，平均目標價爲44.14美元。
Day One Biopharmaceuticals Company Profile
第一天生物製藥公司簡介
(Get Rating)
（獲取評級）
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.
Day One Biopharmaceuticals, Inc是一家臨牀階段的生物製藥公司，爲基因定義癌症患者開發和商業化靶向療法。其主要候選產品是 DAY101，這是一種口服腦穿透劑 II 型泛快速加速纖維肉瘤激酶抑制劑，目前正在針對復發/進行性低度神經膠質瘤兒科患者的 II 期臨牀試驗。
Featured Stories
精選故事
- Get a free copy of the StockNews.com research report on Day One Biopharmaceuticals (DAWN)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ's Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
- 免費獲取 StockNews.com 第一天生物製藥（DAWN）研究報告的副本
- 化石集團：你應該在2023年押注消費者自由裁量權嗎？
- 在業績強勁之後，BJ的批發俱樂部股票走高
- 每月房地產收入即將增加
- 千禧一代投資者的三大股息挑戰者
- Sea Ltd 即將迎來 100% 的反彈，你應該買嗎？
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收第一天生物製藥的新聞和評級 -在下面輸入您的電子郵件地址，通過Marketbeat.com的免費每日電子郵件時事通訊接收Day One Biopharmaceuticals及相關公司的最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。